Home/Pipeline/TROCEPT-02 (ATTR-02)

TROCEPT-02 (ATTR-02)

Not Specified

PreclinicalActive

Key Facts

Indication

Not Specified

Phase

Preclinical

Status

Active

Company

Accession Therapeutics

About Accession Therapeutics

Accession Therapeutics is an emerging private biotech company pioneering a differentiated approach in immuno-oncology with its Trocept platform, a stealth virus technology engineered for tumor-specific entry. The company has advanced its lead candidate, TROCEPT-01 (ATTR-01), into a Phase 1 trial (ATTEST) for solid cancers and is building a broader pipeline. Backed by significant recent funding and led by an experienced team, including immuno-oncology pioneer Bent Jakobsen, Accession is positioning itself to address the limitations of current immunotherapies.

View full company profile

Therapeutic Areas

Oncology

Other Not Specified Drugs

Drug	Company	Phase	Status
New TCM Formulations	China SXT Pharmaceuticals	Research / Pre-clinical	Development
Long-acting Leronlimab	CytoDyn	Preclinical	Phase in progress
Collaborative Program with Ferring	PharmaBiome	Research	Active
Lighthouse Pilot Product	Cipherome	Pilot	Launched 2020
Nitric Oxide + Collagen Delivery	Jellagen	Research	Active
Undisclosed	Authera	Pre-clinical	Active
mRNA Therapeutics Platform Application	Lupagen	Research	Active
PHYRAGO	Handa Pharmaceuticals	Approved	Active
TASCENSO ODT	Handa Pharmaceuticals	Approved	Active
Axulin	Housey Pharmaceutical Research Laboratories	Commercial	Active
PBI-04711	Phoenix Biotechnology	Pre-clinical	Active
Immunology Program	Ignite Biomedical	Discovery	Active